biotx.ai GmbH
Booth number: B52-04
www.biotx.ai
About us
Causal mapping of the genome: Unveiling the genes that cause or influence biological effects, traits, or diseases
Our vision is to disrupt the high-risk biotech business model through a more predictable, data-driven approach. Through causal mapping of the genome, we elucidate the underlying biological mechanisms of diseases and enable robust prediction of clinical trial outcomes.
By curating a comprehensive catalog based on 9,539 Genome-wide association study (GWAS) datasets including 22,376,782 cases across 3,303 diseases, biotx.ai tested all 23,280 genes and more than 10,000 biomarkers for each disease using Mendelian randomization (MR) or colocalization. The platform leverages advanced machine learning to identify clusters, pinpointing the essential causal relationships of drug targets. This process connects drug targets directly to disease biology, uncovering novel candidates with verified causal links to various health conditions.
Since launching its technology in late 2022, biotx.ai has initiated co-developments for novel drug targets as well as helped biotech firms optimize clinical development and secure crucial funding.
Address
Am Mühlenberg 11
14476 Potsdam
Germany
E-mail: info@biotx.ai
Phone: +49 170 3146851
Internet: www.biotx.ai
Contact person:
Dr. Marco Schmidt
E-mail: ms@biotx.ai
Dr. Roman Fudim
E-mail: rf@biotx.ai
Products & Services
biotx.ai has developed a scalable platform that applies causal inference to drug discovery by analyzing extensive datasets (over 22 million cases across 3,300 diseases). The platform:
Integrates public genomic and biomarker data to validate drug targets.
Uses advanced machine learning to uncover causal relationships between targets and diseases.
Simulates large-scale clinical trials in human genetics.
Provides early biochemical signals of clinical efficacy in phase 1 trials.
Supports drug repurposing by identifying promising "shelved" compounds for new therapeutic applications.
By combining causal AI with ligand modeling, biotx.ai bridges the gap between drug targets and disease biology, reducing phase 2 failure rates and improving the efficiency of drug development.